A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2019
Price : $35 *
At a glance
- Drugs FOR-46 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Fortis Therapeutics
- 13 Jun 2019 Planned End Date changed from 1 Apr 2021 to 1 Jul 2020.
- 13 Jun 2019 Planned primary completion date changed from 1 Jan 2021 to 1 May 2020.
- 13 Jun 2019 Status changed from not yet recruiting to recruiting.